Stocks · News reference

Reported Earlier, Quantum BioPharma Approves Debt Settlement Of C$123,487.43 Via Class B Shares At Deemed Price Of C$4.26 Or Lower

Jul 21, 2026, 6:53 AMBenzinga Newsdesk

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Jul 21, 2026, 6:53 AM
Checked: Jul 21, 2026, 6:53 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 2, 2026, 8:11 AMBenzinga Newsdesk
Reported Earlier, Quantum BioPharma Plans To Leave Canadian Exchange While Keeping Nasdaq Listing
Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and
CSE:QNTM QNTM
BenzingaAug 31, 2026, 5:00 PMBenzinga Newsdesk
Rodman & Renshaw Initiates Coverage On Quantum BioPharma with Buy Rating, Announces Price Target of $8
QNTM
BenzingaAug 14, 2026, 6:37 PMBenzinga Newsdesk
Quantum Biopharma shares are trading higher after the company announced it received FDA approval to proceed with its Lucid-MS Phase 2 clinical trial in progressive multiple sclerosis.
QNTM
BenzingaAug 14, 2026, 11:12 AMBenzinga Newsdesk
Quantum BioPharma Says FDA Cleared IND For Lucid-MS Phase 2 Trial In Progressive Multiple Sclerosis; Reports Cash Runway To At Least October 2027
QNTM